Luminescence complementation technology for the identification of MYC:TRRAP inhibitors
Metrics: PDF 764 views | Full Text 1911 views | ?
Edmond J. Feris1,2, John W. Hinds1,2 and Michael D. Cole1,2
1 Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth College, Hanover, NH 03755, USA
2 Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA
|Michael D. Cole,||email:||[email protected]|
Keywords: cancer; drug discovery; targeted therapy; oncogene; transcription factor
Received: May 15, 2021 Accepted: September 04, 2021 Published: October 12, 2021
Mechanism-based targeted therapies have exhibited remarkable success in treating otherwise untreatable or unresectable cancers. Novel targeted therapies that correct dysregulated transcriptional programs in cancer are an unmet medical need. The transcription factor MYC is the most frequently amplified gene in human cancer and is overexpressed because of mutations in an array of oncogenic signaling pathways. The fact that many cancer cells cannot survive without MYC – a phenomenon termed “MYC addiction” – provides a compelling case for the development of MYC-specific targeted therapies. We propose a new strategy to inhibit MYC function by disrupting its essential interaction with TRRAP using small molecules. To achieve our goal, we developed a platform using luminescence complementation for identifying small molecules as inhibitors of the MYC:TRRAP interaction. Here we present validation of this assay by measuring the disruption of TRRAP binding caused by substitutions to the invariant and essential MYC homology 2 region of MYC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.